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Objectives. This study assessed the accuracy of 2% dodecaflu- 
oropentane (EehoGen), an intravenous echocardiographie con. 
trast agent, in identifying myocardial rea at risk and infarct size 
in the canine model of myocardial ischemia. 
Background. Myocardial contrast echocardiography allows de- 
termination of myocardial area at risk and infarct size but 
requires intracoronary injection in humans. The development of 
agents that can be delivered by peripheral intravenous injection 
could enable bedside myocardial contrast echocardiographic as-
sessment of risk area, infarct size and reperfusion. 
Methods. TWo protocols were used. Protocol 1 assessed the 
accuracy of myocardial contrast echocardiography using intrave- 
nous dodecafluoropentane in defining myocardial rea at risk and 
infarct size in the canine model of regional myocardial iscbemia 
versus gross pathologic specimens stained with monastrai blue to 
determine area at risk and triphenyltetrazolium chloride to 
determine the area of necrosis. Protocol 2 assessed the effects of 
repeated injections of dodecafluoropentane (0.5 ml/kg body 
weight, four doses 30 min apart or eight doses 10 min apart) on 
myocardial blood flow and hemodynamic variables. 
Results. Myocardial contrast echocardiography accurately de- 
fined area at risk and infarct size (r = 0.96 vs. triphenyltetrazo. 
lium chloride). Myocardial blood flow remained stable after 
multiple serial injections of dodecafluoropentane. However, a 
significant increase in pulmonary artery pressure and pulmonary 
vascular resistance, along with a decrease in arterial oxygen 
saturation and cardiac output, was seen in dogs that received 
eight injections at 10-min intervals. 
Conclusions. Myocardial contrast echocardiography using in- 
travenous dodecafluoropentane accurately defined myocardial 
area at risk and infarct size. Hemodynamic variables and regional 
myocardial blood flows remained stable when dodecafluoropen- 
tane was injected at 30-min intervals for up to four doses; more 
frequent administration led to cardiopulmonary deterioration. 
Dodecafluoropentane off rs the potential for reliable, noninvasive 
assessment ofreperfusion after therapeutic interventions. 
(J Am Coil Cardiol 1995;26:1340-7) 
Myocardial contrast echocardiography is a promising tech- 
nique for clinical assessment of myocardial perfusion in 
humans (1-4). Ito et al. (5) used myocardial contrast echocar- 
diography to identify the absence of myocardial perfusion 
("no-reflow" phenomenon) in 25% of patients in whom an 
occluded infarct-related artery was successfully opened by 
angioplasty or thrombolytic therapy. Conversely, Sabia et al. 
(6) used myocardial contrast echocardiography to show that 
the myocardium supplied by an occluded infarct-related artery 
may be fully perfused by angiographically invisible collateral 
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channels. These studies established that infarct-related artery 
patency and myocardial perfusion are not necessarily concor- 
dant in humans. Thus, the ability to identify the presence or 
absence of myocardial perfusion by myocardial contrast echo- 
cardiography in the peri-infarct period may offer important 
advantages over simple assessment of infarct-related artery 
patency at catheterization (7). 
Myocardial contrast echocardiography currently requires 
injection of sonicated contrast medium or albumin into the 
aortic root or coronary arteries. Intravenous injection has not 
been feasible because these agents do not cross the pulmonary 
circulation in sufficient concentration to opacify the myocar- 
dium. Recently, a new contrast agent (EchoGen, a 2% emul- 
sion of dodecafluoropentane) has been developed that has 
excellent acoustic properties and easily crosses the pulmonary 
circulation (8,9). The present study was undertaken 1) to 
determine whether this agent accurately identifies myocardial 
area at risk and infarct size in the canine model of acute 
ischemia/reperfusion, and2) to assess the effects of this agent 
on hcmodynamic variables and regional myocardial b ood flow. 
~')1995 b~ the Anlcriean ( ~llegc ~1 ( ,Li,h,M~, 0735-1()97/95/$9.5(} 
[1735-1097(95)003[!6-O 
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Methods 
Experimental preparation. Twenty-five conditioned mon- 
grel dogs, weighing 20 to 33 kg, were studied. The dogs were 
anesthetized with intravenous sodium pentobarbital (30 mg/kg 
body weight), intubated and ventilated with room air. Anes- 
thesia was maintained throughout the experiment with sodium 
pentobarbital, as required to abolish the corneal reflex. Heart 
rate and the electrocardiogram were continuously monitored 
(Electronic for Medicine VR-12). Both femoral arteries and 
the right femoral vein were exposed and cannulated with 8F 
sheaths. A 7F thermodilution catheter was advanced into the 
left pulmonary artery under fluoroscopic guidance for assess- 
ment of right heart pressures and cardiac output. A 7F pigtail 
catheter was advanced into the ascending aorta for arterial 
pressure monitoring. The dogs were then randomized to one of 
two protocols. 
Protocol 1. Protocol 1 (n = 15) was designed to determine 
the accuracy of intravenous dodecafluoropentane i  defining 
myocardial area at risk and infarct size. After anesthesia nd 
placement of hemodynamic monitoring catheters, a left thora- 
cotomy was performed, and the heart was suspended in a 
pericardial cradle. A monofilament suture was placed around 
the proximal eft anterior descending coronary artery to allow 
controlled occlusion and reperfusion. A transit ime flow probe 
(Transonics), was used for continuous monitoring of epicardial 
coronary flow, and a heparinized Silastic catheter was inserted 
into the left atrial appendage for injection of radiolabeled 
microspheres for determination of regional myocardial blood 
flow. 
After a period of stabilization, baseline variables were 
obtained, including heart rate, arterial blood pressure, temper- 
ature and arterial blood gases. Each dog then underwent 
90-min occlusion of the left anterior descending coronary 
artery, followed by 4 h of reperfusion. Regional myocardial 
blood flow measurements with microspheres and myocardial 
contrast echocardiography using a single injection of dodeca- 
fluoropentane (0.5 ml/kg) were performed at baseline, 25 min 
after occlusion and after 4 h of reperfusion. Final measure- 
ments were then repeated after maximal coronary vasodilation 
with intracoronary adenosine (140 /xg/kg per min). Other 
investigators (10) have shown that maximal coronary vasodila- 
tion with intravenous dipyridamole nhances the accuracy of 
infarct size as determined by myocardial contrast echocardiog- 
raphy within 3 h of reperfusion. We used intracoronary 
adenosine because it causes maximal coronary vasodilation 
without systemic hypotension (11). A single injection of do- 
decafluoropentane was used in protocol 1 at each time period. 
A dose of 0.5 ml/kg was selected on the basis of previous 
studies in dogs showing myocardial opacification at this dose 
(8,9). 
Protocol 2. Dodecafluoropentane is known to be associ- 
ated with transient hypotension i  dogs (8,9). In the clinical 
setting, repeated injections of dodecafluoropentane may be 
needed to evaluate different coronary vascular beds. There- 
fore, protocol 2 was performed to define the effects of sequen- 
tial injections of dodecafluoropentane o  hemodynamic vari- 
ables and myocardial blood flow in 10 closed chest dogs. After 
anesthesia, five dogs were randomized to pretreatment with 
methylprednisolone (10 mg/kg intravenously) and cimetidine 
(300 mg intravenously) to attenuate the hypotensive r sponse 
associated with fluorocarbon administration i dogs (12). A 
5-MHz transesophageal chocardiographic probe (Interspec) 
was used for continuous monitoring of left ventricular func- 
tion. Baseline measurements of body temperature, arterial 
blood pressure, heart rate, pulmonary artery pressure, pulmo- 
nary capillary wedge pressure, thermodilution cardiac output, 
arterial blood gases and regional myocardial blood flow (see 
later) were recorded. Multiple sequential peripheral intrave- 
nous injections of dodecafluoropentane (0.5 ml/kg) were ad- 
ministered at either four doses 30 rain apart (n = 4) or eight 
doses 10 rain apart (n = 6). Hemodynamic variables were 
assessed at baseline and 5 rain after each dose. Myocardial 
blood flow determinations using radiolabeled microspheres 
were made at baseline, at the midway point (after dose 2 of the 
four-dose protocol or after dose 4 of the eight-dose protocol) 
and after the final dose. 
Myocardial contrast echocardiography. Myocardial con- 
trast echocardiography was performed using a 2.5-MHz linear 
phased array transducer (Hewlett-Packard Sonos 1500). A 
water-filled latex glove was used to provide an acoustic inter- 
face between the transducer and the anterior myocardium. 
Gain settings were adjusted to optimize image quality and were 
then held constant for each dog. Midventricular short-axis 
images were obtained at baseline and during peripheral intra- 
venous injection of dodecafluoropentane (0,5 ml/kg). Dodeca- 
fluoropentane has a low boiling point and therefore is a liquid 
at room temperature but becomes a gas at body temperature, 
with a reported mean microbubble size -3/xm and a mean 
concentration of1012 microbubbles/ml (8,9). Contrast echocar- 
diography was performed at baseline, 25 min after start of 
occlusion and 4 h after reperfusion (before and after adenosine). 
Studies were recorded on videotape for subsequent analysis. 
Myocardial contrast echocardiographic studies were ana- 
lyzed using software built into the echocardiographic system. 
The total area of the left ventricular myocardium was manually 
traced in the midventricular short-axis view. The perfusion 
defect, defined as the area without myocardial contrast uptake 
during occlusion, was traced to determine area at risk (ex- 
pressed as percent of left ventricular area). Perfusion defects 
after 1 and 4 h of reperfusion were traced to determine infarct 
size (expressed as percent of myocardial area and percent of 
risk area). All tracings were performed by an experienced 
observer (P.A.G.) with no knowledge of gross pathologic 
findings. 
Regional myocardial blood flow. Regional myocardial 
blood flow was assessed by serial eft atrial injections of 15-/xm 
microspheres (DuPont NEN) labeled with chromium-51 (base- 
line), niobium-95 (occlusion) and cerium-141 (reperfusion). 
Approximately 2 × 106 microspheres were used for each 
injection. Reference femoral artery blood samples were ob- 
tained using a Harvard pump at a withdrawal rate of 
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7.9 ml/min. In dogs randomized to protocol 1, myocardial 
blood flow was determined in samples of the slice best 
corresponding to the short-axis echocardiographic view. In 
dogs randomized to protocol 2, myocardial blood flow was 
determined in all slices of the left ventricle. For protocol 1, the 
representative slice was sectioned into four zones: a central 
ischemic zone, two lateral ischemic zones and a nonischemic 
zone (posterior wall). Studies performed by us (11) and others 
(12) have demonstrated that the anatomic entral ischemic 
zone (unstained by monastral blue) is usually the region with 
the most impaired regional myocardial blood flow. For proto- 
col 2, each slice was sectioned into four zones: anterior, septal, 
lateral and posterior walls. In both protocols, each zone was 
further subdivided into endocardial, midmyocardial nd epi- 
cardial sections weighing 0.5 to 1.0 g. Myocardial sections and 
reference blood samples were counted for 5 min each in a 
multichannel auto-gamma scintillation spectrometer (Packard 
Instrument Co.) with background correction, and the overlap- 
ping radioactivity between isotopes was corrected using the 
matrix correction method (Compusphere Software, Packard 
Instrument Co.) (13). Myocardial blood flow (Om [ml/min per 
g tissue]) was calculated as Qm = (Cm x Or)/(Cr x Wt), 
where Cm = total number of counts in tissue sample; Or = 
reference arterial sample withdrawal rate; Cr = number of 
counts in reference blood sample; and Wt = weight of tissue 
sample (14). 
Assessment of area at risk and infarct size. Gross patho- 
logic assessment ofmyocardial rea at risk and infarct size was 
performed inall dogs randomized toprotocol 1 by established 
methods routinely used in our laboratory (15,16) and by others 
(12,17). After the 4-h reperfusion period, the left anterior 
descending coronary artery was again occluded, and monastral 
blue stain (1 mg/kg) was injected into the left atrium for 
determination f myocardial area at risk. The dog was imme- 
diately killed with an overdose of pentobarbital (120 mg/kg), 
and the heart was removed and sectioned into four to six slices 
parallel to the atrioventricular g oove from apex to base. The 
occluder emained in place until the heart was sectioned to 
prevent spillover of monastral blue stain into the area at risk. 
The right ventricle was dissected away, and each left ventric- 
ular slice was weighed and its thickness measured. Each slice 
was photographed (Ektachrome-64, Kodak) for later determi- 
nation of risk area (area unstained by monastral blue). To 
determine infarct size, each slice was incubated in 2% tri- 
phenyltetrazolium chloride for 15 min at 37°C. Each slice was 
then photographed again for determination of infarct size. 
Triphenyltetrazolium chloride stains normal tissue dark red; 
infarcted tissue is unstained. Percent risk area (unstained by 
monastral blue) and infarct area (unstained by triphenyltetra- 
zolium chloride) were measured using a digitizing pad and 
dedicated computer software (Sigma Scan, Jendel Scientific). 
Myocardial area at risk and infarct size are reported for the 
pathologic slice that matches the short-axis echocardiographic 
view of the left ventricle. 
Data analysis. Hemodynamic data, regional myocardial 
blood flow and gross pathologic and mvocardial contrast 
echocardiographic f ndings were analyzed separately and in 
blinded manner. For protocol 1, linear regression was used to 
compare area at risk and infarct size by myocardial contrast 
echocardiography with those obtained by gross pathologic 
studies. Repeated measures analysis of variance was used to 
analyze group differences inhemodynamic variables. In proto- 
col 2 the dogs were divided in two groups (four and eight 
injections). The use of steroids decreased the duration of the 
hypotensive r sponse to dodecafluoropentane but did not alter 
any other variable. Therefore, dogs treated and those un- 
treated with steroids are considered together. Data are re- 
ported as mean value _+ SD; p -< 0.05 was considered 
statistically significant. 
Results  
Protocol 1. Regional myocardial blood flow. Fifteen dogs 
were subjected to 90 min of ischemia followed by 4 h of 
reperfusion. One dog did not survive the reperfusion period 
and was excluded from analysis. Two other dogs were excluded 
because of inadequate myocardial opacification. Myocardial 
opacification was excellent in five dogs, good in five and 
adequate in two. Transmural myocardial blood flow in the 
central ischemic zone (anterior wall) during coronary occlusion 
was 0.1 _ 0.1 ml/min per g. Transmural blood flow in the 
central ischemic zone 4 h after epeffusion was lower than that 
in the nonischemic zone (0.6 z 0.5 vs. 1.2 _+ 0.5 ml/min per g, 
p < 0.0001). However, there was wide variation in flows 
between dogs; some had markedly depressed flows after 
reperfusion, suggesting the presence of profound microvascu- 
lar dysfunction and "no-reflow" phenomenon (18,19), whereas 
others had significantly improved transmural b ood flow after 
reperfusion. 
Determination of myocardial area at risk and area of necrosis. 
Figure 1 shows representative contrast echocardiographic and 
pathologic images of a large myocardial area at risk and 
subsequent subendocardial infarction 4 h after reperfusion. 
Figure 2 shows images from a dog with reperfusion of the 
myocardial area at risk and no pathologic evidence of infarc- 
tion. Figure 3 compares the values for myocardial area at risk 
and infarct area as assessed by contrast echocardiography and 
gross pathologic studies. Myocardial contrast echocardiogra- 
phy accurately defined myocardial area at risk compared with 
monastral blue stain (33 _+ 9% vs. 31 + 8%, p = NS). Four 
hours after reperfusion, contrast echocardiography accurately 
defined infarct area (43 _-2- 33% vs. 47 _ 33% area at risk, p = 
NS; 17 _+ 10 vs. 16 ± 13% left ventricular area, p = NS). As 
shown in Figure 4, good correlation existed between contrast 
echocardiographic and pathologic infarct area, expressed as 
percent area at risk 4 h after reperfusion (SEE 9.7%). Intra- 
coronary adenosine 4 h after repeffusion only marginally 
improved the accuracy of infarct area determination (SEE 
8.6%). In contrast, infarct area was underestimated by contrast 
echocardiography 1 hafter reperfusion (22 _+ 26 vs. 47 __ 33% 
area at risk, p < 0.05; 10 _+ 10 vs. 16 _+ 13% left ventricular 
area, p = 0.06). 
JACC Vol. 26, No. 5 GRAYBURN ET AL. 1343 
November 1, 1995:1340-7 CONTRAST ECHOCARDIOGRAPHY AND INFARCT SIZE 
Figure 1. Representative examples 
from a study dog. The perfusion 
defect on myocardial contrast 
echocardiography during occlusion 
(arrows, top left) closely correlates 
with the area at risk identified by 
monastral blue stain (bottom left). 
The perfusion defect on myocar- 
dial contrast echocardiography 4 h
after eperfusion (top right) closely 
matches the infarct size of the area 
unstained by triphenyltetrazolium 
chloride (bottom right). Note the 
preserved epicardial rim clearly 
identified by myocardial contrast 
echocardiography and pathologic 
samples. 
Protocol 2. Hemodynamic effects. A single injection of 
dodecafluoropentane produced a transient increase in heart 
rate (from 134 _+ 15 to 156 _+ 17 beats/min, p = 0.002) over 
-30 s as well as a decrease in mean arterial pressure (from 
142 _ 19 to 112 _+ 27 mm Hg, p = 0.0004) that was short lived 
(30 to 60 s) in steroid-treated dogs but lasted longer (2 to 
3 rain) in those not treated with steroids. Hemodynamic data 
are summarized in Table 1. Four dodecafluoropentane i j c- 
tions at 30-min intervals did not produce significant changes in 
hemodynamic variables or arterial oxygen saturation. Con- 
versely, dogs that received up to eight injections of dodecaflu- 
oropentane at 10-rain intervals howed a progressive increase 
in pulmonary artery pressure, along with a significant decrease 
in arterial oxygen saturation. These changes were accompanied 
by a progressive decrease in mean arterial pressure, stroke 
volume and cardiac output. Moreover, two dogs were unable to 
receive all eight injections because of severe respiratory dis- 
tress and bradycardia fter the seventh injection. Pulmonary 
capillary wedge pressure did not change in dogs that received 
injections at 10-rain intervals. 
There were no changes in regional wall motion in dogs that 
received four injections of dodecafluoropentane at 30-rain 
Figure 2. Myocardial contrast 
echocardiographic images from an- 
other dog showing complete reper- 
fusion after release of occlusion. 
Left, Area at risk (arrows) during 
occlusion. Right, At 4 h after eper- 
fusion, no residual perfusion defect 
is seen. Pathologic examination 
showed a similar area at risk with 
no evidence of necrosis by tri- 
phenyltetrazolium chloride. 
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Figure 3. Myocardial risk area and infarct size according topathologic 
examination (white columns), myocardial contrast echocardiography 
1 h after repeffusion (solid columns) and myocardial contrast echo- 
cardiography 4 h after repeffusion (hatched columns). Risk area is 
expressed aspercent of left ventricle (risk area/left ventricle [AR/LV]). 
Infarct size is expressed aspercent of left ventricle (area of necrosis/ 
left ventricle [AN/LV]) and percent of risk area (area of necrosis/risk 
area [AN/AR]). Risk area is accurately defined by myocardial contrast 
echocardiography. Infarct size is underestimated by myocardial con- 
trast echocardiography 1  after eperfusion but is accurate 4 h after 
reperfusion. Data shown are mean value (columns) + SD vertical 
bars). *p < 0.05. 
intervals. In contrast, marked paradoxical septal motion oc- 
curred in all animals that received odecafluoropentane t 
10-min intervals. This finding appeared after the third or 
fourth injection and was temporally related to increased 
pulmonary artery pressures and hypoxemia. Subsequent injec- 
tions of dodecafluoropentane resulted in moderate to severe 
global left ventricular hypokinesia. 
Effects on myocardial blood flow. Myocardial blood flow 
remained stable in all left ventricular slices despite hemody- 
namic deterioration. Blood flow was similar in all four myo- 
Figure 4. Regression plot comparing infarct size as percent of risk 
area (area of necrosis/risk area [AN/AR]) by myocardial contrast 
echocardiography (MCE) versus pathologic examination (triphenyltet- 
razolium chloride) 4 h after reperfusion. Excellent correlation was 
achieved, with SEE 9.7%. Intracorona~ adenosine only marginally 
improved the correlation (r = 0.97, SEE 8.6%, not shown). 
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cardial walls. Figure 5 shows the transmural myocardial blood 
flow in the anterior wall for dogs treated with four injections at 
30-rain intervals and those with eight injections at 10-min 
intervals. 
Gross pathologic findings. Postmortem gross examination 
of the lungs in dogs receiving injections at 10-rain intervals 
showed marked accumulation of dodecafluoropentane, which 
could be expressed as a foamy substance on gentle manual 
compression of the lungs. In contrast, there was no grossly 
apparent accumulation fdodecafluoropentane in the lungs of 
dogs that received four doses 30 min apart. 
Discuss ion  
Previous tudies in dogs have shown that myocardial con- 
trast echocardiography is accurate in determining myocardial 
area at risk and infarct size after injection of a contrast agent 
into the coronary arteries (10,20,21), ascending aorta (22,23) 
and left (24) and right atrium (24,25) (with intravenous 
dipyridamole). Recently, Porter and Xie (26) showed the 
feasibility of myocardial opacification by peripheral intrave- 
nous injection using albumin sonicated with gases of low 
diffusion rates and low blood solubility. The present study 
demonstrates that peripheral intravenous injection of dodeca- 
fluoropentane accurately determines myocardial area at risk 
and area of necrosis in the canine model of regional myocar- 
dial ischemia. To our knowledge, this is the first report of 
accurate valuation of myocardial rea at risk and infarct size 
using an intravenous agent hat does not require the use of 
radioisotopes. 
Clinical applications. The ability to define myocardial per- 
fusion by contrast echocardiography using an intravenous 
agent offers several advantages in the clinical setting. The 
technique isnoninvasive and can be used at the bedside, in the 
emergency room or in the coronary care unit. The ability to 
define the area at risk may be crucial in deciding whether to 
administer thrombolytic drugs, particularly in patients with 
relative contraindications and a small risk area in which the 
degree of myocardial salvage with reperfusion would be mod- 
est. This technique could also determine the need for primary 
angioplasty in the setting of a very large perfusion defect. In 
addition, demonstration of reduced perfusion defect after 
pharmacologic or mechanical intervention should have enor- 
mous prognostic implications because perfusion of the infarct 
zone has been shown (6,27,28) to predict late recovery of left 
ventricular function. Finally, immediate identification of fail- 
ure to achieve perfusion of the infarct zone could become 
important in identifying patients who might benefit from 
salvage angioplasty. 
Temporal relation between infarct size and perfusion de- 
fect. We found good correlation between gross pathologic 
determination of area of necrosis and myocardial contrast 
echocardiographic perfusion defect 4 h after reperfusion. 
Conversely, the peffusion defect 1 h after repeffusion under- 
estimated final infarct size. These data generally confirm the 
findings of Villanueva et al. (10) who showed underestimation 
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Table 1. Hemodynamic Data After Repeated Dodecafluoropentane Injections 
Injection at 30-min Intervals Injection at 10-min Intervals 
Baseline First Midpoint Final Baseline First Midpoint Final 
HR (beats/min) 129 _+ 9 128 ± 22 125 _+ 12 125 : 23 136 _+ 18 138 _+ 25 136 _+ 24 119 + 14 
MAP (mm Hg) 134 ± 12 123 + 45 124 + 27 127 _+ 20 147 _+ 14 114 _+ 63 I l l  _+ 29 77 -- 50* 
PA (mm Hg) 17 _+ 3 17 + 5 20 ± 5 22 + 5 14 _+ 3 15 + 4 23 _+ 6 33 _+ 8"t 
PCWP (mm Hg) 8 :3  8+4 8_+4 8+3 7_+2 6_+3 9-+3 8-+2 
CO (liters/rain) 1.5 - 0.3 1.6 ~ 0.6 1.4 + 0.5 1.2 +_ 0.5 1.9 -+ 0.4 1.6 -+ 0.7 1.6 _+ 0.6 1.0 _+ 0.2* 
Stroke volume (ml) 12 + 3 12 = 3 11 + 4 10 +- 4 15 _+ 2 12 -+ 5 11 _+ 3 8 + 1" 
PVR (ram Hg/ml per min per liter) 0.2±0.1 0.1 = 0.1 0.2+11.1 0.3-+0.1 0.1_+0.3 0.2-+0.1 0.3-+0.1 0.7-+0.3"1" 
SVR (mm Hg/ml per min per liter) 2,1 _+ 0.4 1.7 +- 0.5 2.2 + 1. I 2.7 -+ 1.3 2.1 -+ 0.4 1.6 -+ 1.0 2.0 -+ 0.4 2.2 -+ 1.4 
Oxygen saturation (%) 96 + I 96 ± l 95 : 1 93 -+ 3 96 _+ 1 9l -+ 1 87 -+ 3 83 _+ 1'9 
*p < 0.05, difference within group tp < 0.05, difference between groups. Data presented are mean value _+ SD. CO = cardiac output; HR = heart rate; MAP = 
mean arterial pressure: PA = mean pulmonau, arte~ pressure; PCWP = pulmonary capillary, wedge pressure; PVR = pulmonary vascular resistance; SVR = systemic 
vascular esistance. 
of final infarct size when myocardial contrast echocardiogra- 
phy was performed up to 3 h after reperfusion. They proposed 
that intact microcirculation i the peri-infarct zone allowed 
echogenic microbubbles into tissue that was irreversibly dam- 
aged, therefore underestimating infarct size. They also showed 
that administration of dipyridamole markedly improved the 
relation between perfusion defect and infarct size, presumably 
by vasodilation of the nonischemic vascular bed, such that the 
echogenic microbubbles were shunted away from the peri- 
infarct zone. In our study, intracoronary adenosine caused only 
a marginal improvement in the correlation between perfusion 
defect size and pathologic infarct size 4 h after rcperfusion. 
This finding is supported by the elegant studies of Ambrosio et 
al. (29) who examined the time course of the no-reflow 
phenomenon in the canine model of regional myocardial 
ischemia. They found a progressive deterioration i perfusion 
to areas that were initially well perfused uring the reactive 
hyperemic period immediately after repeffusion. Areas that 
demonstrated this progressive decrease in perfusion had neg- 
ligible myocardial blood flow by 3.5 h into reperfusion. Histo- 
Figure 5. Transmural nterior wall myocardial b ood flow (RMBF) at 
baseline, after the midpoint of the protocol and after the final 
dodecafluoropentane inj ction. There were no differences in dogs 
receiving eight (open circles) or four injections (solid circles). Data 
were similar for subendocardial blood flow (not shown). 
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logic data showed this finding to be associated with neutrophil 
accumulation and capillary plugging relatively late in the 
course of reperfusion. 
Our results differ slightly from those of Villanueva et al. 
(10) in that we showed a strong correlation between the 
contrast echocardiographic perfusion defect and pathologic 
infarct size 4 h after reperfusion, whereas they did not find 
such a relation 3 h after reperfusion. This result could be 
explained by two factors: 1) It is possible that the time course 
of the no-reflow phenomenon is not completed until 4 h of 
reperfusion; and 2) differences in the experimental model 
could have influenced the results. We specifically used a 
90-min occlusion period to allow a wide range of myocardial 
salvage; Villanueva et al. used a 3-h occlusion period. They 
power injected albuminex into the left main coronary artery; 
we allowed physiologic peffusion by dodecafluoropentane by 
intravenous injection. However, it is more likely that differ- 
ences between the contrast agents accounted for the different 
results. For example, recent images from cat mesenteric arte- 
rioles showed (30) that dodecafluoropentane microbubbles 
appear larger than red blood cells, suggesting that the micro- 
bubbles expanded in vivo. It is possible that this increase in 
particle size prevented odecafluoropentane from penetrating 
areas of significant microvascular injury, thereby facilitating 
assessment of final infarct size in our study. In humans, 
because of existing collateral channels and uncertainty as to 
the exact time of arterial occlusion, the temporal relation 
between myocardial perfusion defect and infarct size is un- 
known. Nevertheless, even if contrast echocardiography under- 
estimates infarct size early after thrombolytic therapy in hu- 
mans, the demonstration that reperfusion has occurred has 
important prognostic and therapeutic mplications. 
Persistence of myocardial contrast effect. Because of its 
density and low diffusivity, dodecafluoropentane persists in the 
circulation for much longer than air-based echocardiographic 
contrast agents, facilitating transpulmonary passage and sub- 
sequent myocardial opacification. In the present study, myo- 
cardial opacification lasted for up to 20 min after a single 
intravenous injection. One explanation for this prolonged 
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contrast effect is that dodecafluoropentane, like other fluoro- 
carbons, might increase vascular permeability and enter the 
extravascular space. Alternatively, the microbubbles may ex- 
pand in vivo and become trapped in the microvasculaturc. 
Recent studies (30) in a cat mesenteric preparation showed 
that in vivo dodecafluoropentane microbubbles are consider- 
ably larger than red blood cells, and they appeared to adhere 
to the endothelial surface of precapillary arterioles, perhaps 
due to surfactants used in the preparation of this agent. In the 
present study, regional myocardial blood flow was not de- 
creased during sequential dodecafluoropentane i jections, 
suggesting that the exceptional persistence of myocardial con- 
trast effect is not simply due to "plugging" of the microcircu- 
lation. Nevertheless, the lack of change in rest regional myo- 
cardial blood flow does not completely exclude the possibility 
of some degree of microvascular occlusion, particularly in the 
lungs, where pulmonary pressures and vascular resistance 
increased markedly in dogs given eight injections of dodeca- 
fluoropentane at 10-rain intervals. Further research is needed 
to confirm the mechanism of this unusually long persistence of
myocardial contrast agent. 
Hemodynamic variables. Dodecafluoropentane is cleared 
through the lungs, where it is exhaled unchanged with an 
elimination half-life of -20 rain. In our study, administration 
of dodecafluoropentane t 10-min intervals resulted in hemo- 
dynamic deterioration characterized by increased pulmonau' 
artery pressure and pulmonary vascular esistance, decreased 
arterial oxygen saturation, cardiac output and stroke volume 
and no change in pulmonary capillary wedge pressure. These 
hemodynamic changes were accompanied by paradoxic septal 
motion as well as gross accumulation of dodecafluoropentane 
in the lungs. In contrast, administration of dodecafluoropen- 
tane at 30-min intervals did not result in significant hemody- 
namic changes or wall motion abnormalities, nor did it lead to 
accumulation i the lungs. These findings, along with the fact 
that myocardial blood flow was not changed by frequent 
administration of dodecafluoropentane, suggest hat the ad- 
verse hemodynamic effects were related to inadequate pulmo- 
nary clearance at a frequent dosing interval. Thus, in the 
clinical setting, this agent should not be administered at high 
doses at intervals <30 rain. 
Study limitations. We did not compare myocardial con- 
trast echocardiography with radionuclide methods of assessing 
myocardial perfusion defects, such as technetium-99m (Tc- 
99m) sestamibi (31,32). Although Tc-99m sestamibi isaccurate 
in identifying risk area and infarct area, its use in the clinical 
setting has been limited by technical and economic onsider- 
ations. Because of its slow washout from the myocardium, 
Tc-99m sestamibi isnot suitable for multiple sequential studies 
before and after thrombolytic therapy. In contrast, myocardial 
contrast echocardiography using an intravenous agent does not 
involve radiation, can be done at the bedside and allows 
sequential studies. 
We did not perform a dose-ranging study to carefully 
elucidate the most appropriate dose or dosing interval. More- 
over, it is uncertain whether the hemodynamic effects of 
frequent dodecafluoropentane administration seen in the 
present study will be clinically relevant because perfluorocar- 
bon emulsions are known to cause hypotension i dogs (11) 
but not humans (33). Although initial reports (34) on the use 
of dodecafluoropentane t lower doses (0.1 ml/kg) in clinical 
trials do not show a hypotensive r sponse, these doses did not 
produce myocardial opacification. Since the present study was 
performed, a new method of preactivating dodecafluoropen- 
tane during injection has allowed us to achieve myocardial 
opacification in dogs at doses as low as 0.02 ml/kg without 
hemodynamic effects (unpublished data). Thus, although there 
is much to be learned about the optimal dosage, safety and 
efficacy of this agent, it appears that myocardial contrast 
echocardiography using a peripheral intravenous agent is 
feasible and offers the potential to accurately measure myo- 
cardial area at risk and infarct size. 
Conclusions. Myocardial contrast echocardiography after 
intravenous administration ofdodecafluoropentane is accurate 
in assessing myocardial area at risk and infarct size in the 
canine model of regional myocardial ischemia. Serial injections 
of dodecafluoropentane t 10-rain intervals caused profound 
hemodynamic deterioration; however, serial injections at 30- 
min intervals were well tolerated. The ability to perform 
myocardial contrast echocardiography from a peripheral intra- 
venous approach may become clinically useful in the assess- 
ment of myocardial area at risk and final infarct size in the 
setting of acute myocardial infarction. 
References 
1. Meerbaum S. Myocardial contrast wo-dimensional echocardiography: a 
complement to coronary angiography. J Am Coll Cardiol 1988;12:935-6. 
2. Moore CA, Smucker ML, Kaul S. Myocardial contrast echocardiography in 
humans. 1. Safety: a comparison with routine coronary arteriography. J Am 
Coil Cardiol 1986;8:1066-72. 
3. Keller MW, Glasheen W, Smucker ML, Burwell LR, Watson DD, Kaul S. 
Myocardial contrast echocardiography in humans. 1I. Assessment of coro- 
nary blood flow reserve. J Am Coil Cardiol 1988;12:925-34. 
4. Sabia P J, Powers ER, Jayaweera AR, Ragosta M, Kaul S. Functional 
significance of collateral blood flow in patients with recent acute myocardial 
infarction. Circulation 1992;85:2080-9. 
5. lto H, Tomooka T, Sakai N, et al. Lack of myocardial perfusion immediately 
after successful thrombolysis: a predictor of poor recovery of left ventricular 
function in anterior myocardial infarction. Circulation 1992;85:1699-705. 
6. Sabia PJ, Powers ER, Ragosta M, Sarembock I J, Burwell LR, Kaul S. An 
association between collateral blood flow and myocardial viability in patients 
with recent myocardial infarction. N Engl J Med 1992;327:1825-31. 
7. Lincoff AM, Topoi EJ. Illusion of repert'usion: does anyone achieve optimal 
reperfusion during acute myocardial infarction? Circulation 1993;88:1361-74. 
8. DeMaria AN, Dittrich H, Kwan OL, Kimura B. Myocardial opacification 
produced by peripheral venous injection of a new ultrasonic ontrast agent 
[abstract], Circulation 1993;88 Suppl I:1-401. 
9. Beppu S, Matsuda H, Shishido T, Miyatake K. Success of myocardial 
contrast echocardiography by peripheral venous injection method: visualiza- 
tion of area at risk [abstract]. Circulation 1993;88 Suppl 1:1-401. 
Ill. Villanueva FS, Glasheen WP, Sklenar J, Kaul S. Characterization f spatial 
patterns of flow within the reperfused myocardium by myocardial contrast 
echocardiography: implications in determining extent of myocardial salvage. 
Circulation 1993;88:2596-606. 
11. Velasco CE, Turner M, Cobb M, Virmani R, Forman MB. Myocardial 
JACC Vol. 26, No. 5 GRAYBURN ET AL. 1347 
November 1, 1995:1340-7 CONTRAST ECHOCARDIOGRAPHY AND INFARCT SIZE 
reperfusion i jury in the canine model after 40 minutes of ischemia: effect of 
intracoronary adenosine. Am Heart J 1991;122:1561-70. 
12. Forman MB, Bingham S, Kopelman HA, et al. Reduction of infarct size with 
intracoronary perfluorochemical in a canine preparation of reperfusion. 
Circulation 1985;71:1060-8. 
13. Bajaj AK, Cobb MA, Virmani R, Gay JC, Light RT, Forman MB. Limitation 
of myocardial reperfusion i jury by intravenous perfluorocbemicals: role of 
neutrophil activation. Circulation 1989;79:645-56. 
14. Heymann MA, Payne BD, Hoffman J1, Rudolph AM. Blood flow measure- 
ments with radionuclide-labeted particles. Prog Cardiovasc Dis 1977;20:55- 
79. 
15. Velasco CE, Jackson EK, Morrow JA, Vitola JV. Inagami T, Forman MB. 
Intravenous adenosine suppresses cardiac release of endothelin after myo- 
cardial ischaemia nd reperfusion. Cardiovasc Res 1993;27:121-7. 
16. Velasco CE, Yanagisawa M, Williamson JL, Triana JF. Cardioprotective 
action of endothelin-I during ischemia ]abstract]. Circulation 1993;88 Suppl 
I:I-544. 
17. Ovize M, Przyklenk K, Hale SL, Kloner RA. Preconditioning does not 
attenuate myocardial stunning. Circulation 1992;85:2247-54. 
18. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after 
temporary coronary occlusion in the dog. J Clin Invest 1974;54:1496-508. 
19. Willerson JT, Watson JT, Hutton 1, Templeton GH, Fixler DE. Reduced 
myocardial reftow and increased coronary vascular resistance following 
prolonged myocardial ischemia in the dog. Circ Res 1975;36:771-81. 
20. Kaul S, Pandian NG, Okada RD, Pohost GM, Weyman AE. Contrast 
echocardiography in acute myocardial ischemia: I. In vivo determination f 
total left ventricular "area at risk." J Am Coil Cardiol 1984;4:1272-82. 
21. Sakamaki T, Tei C, Meerbaum S, et al. Verification of myocardial contrast 
two-dimensional echocardiographic assessment of peffusion defects in isch- 
emic myocardium. J Am Coil Cardiol 1984;3:34-8. 
22. Kemper AJ, O'Boyle JE, Sharma S, et al. Hydrogen peroxide contrast- 
enhanced two-dimensional echocardiography: real-time in vivo delineation 
of regional myocardial perfusion. Circulation 1983;68:6(13-11. 
23. Kemper AJ, O'Boyle JE, Cohen CA, Taylor A, Parisi AF. Hydrogen 
peroxide contrast echocardiography: quantification i -vivo of myocardial risk 
area during coronary occlusion and of the necrotic area remaining after 
myocardial reperfusion. Circulation 1984;70:309-17. 
24. Villanueva FS, Glasheen WP, Sklenar J, Kaul S. Assessment of risk area 
during coronary occlusion and infarct size after reperfusion with myocardial 
contrast echocardiography using left atrial and right atrial injections of 
contrast. Circulation 1993;88:596-604. 
25, Villanueva FS, Glasheen WP, Sklenar J, Jayaweera AR, Kaul S. Successful 
and reproducible myocardial opacification during two-dimensional echocar- 
diography from right heart injection of contrast. Circulation 1992;85:1557-64. 
26, Porter TR, Xie F. Visually discernible myocardial echocardiographic con- 
trast after intravenous injection of sonicated extrose albumin microbubbles 
containing high molecular weight, less soluble gases. J Am Coil Cardiol 
1995;25:509-15. 
27. Ragosta M, Camarano G, Kaul S, Powers ER, Sarembock I J, Gimple LW. 
Microvascular integrity indicates myocellular viability in patients with recent 
myocardial infarction: new insights using myocardial contrast echocardiog- 
raphy. Circulation 1994;89:2562-9. 
28. Camarano G, Ragosta M, Gimple LW, Powers ER, Kaul S. Identification of
viable myocardium with contrast echocardiography in patients with poor left 
ventricular systolic function caused by recent or remote myocardial infarc- 
tion. Am J Cardiol 1995;75:215-9. 
29. Ambrosio G, Weisman HF, Mannisi JA, Becker LC. Progressive impairment 
of regional myocardial perfusion after initial restoration of postischemic 
blood flow. Circulation 1989;80:1846-61. 
30. Gong Z, Giraud G, Pantely G, Kenny A, Sahn DJ. Time course of chamber 
and myocardial opacification with EchoGen: a videodensitometric study in 
monkeys with microvascular visualization studies in a cat mesentery model 
[abstract]. Circulation 1994 Suppl I;90:1-556. 
31. Gibbons RJ, Verani MS, Behrenbeck T, et al. Feasibility of tomographic 
9'~mTc-hexakis-2-methoxy-2-methylpropyl-isonitrile maging for the assess- 
ment of myocardial area at risk and the effect of treatment in acute 
myocardial infarction. Circulation 1989;80:1277-86. 
32. Borges-Neto S, Puma J, Jones RH, et al. Myocardial perfusion and ventric- 
ular function during total coronary artery occlusion in humans: acomparison 
with rest and exercise radionuclide studies. Circulation 1994;89:278-84. 
33. Forman MB, Perry JM, Wilson BH, et al. Demonstration of myocardial 
reperfusion i jury in humans: results of a pilot study utilizing acute coronary 
angioplasty with pcrfluorochemical in anterior myocardial infarction. J Am 
Coil Cardiol 1991;18:911-8. 
34. Cotter B, Kwan OL, Kimura B, et al. Evaluation of the efficacy, safety, and 
pharmacokinetics of QW 3600 (EchoGen) in man [abstract]. Circulation 
1994;90 Suppl I:[-555. 
